12:00 AM
Jul 29, 2013
 |  BC Week In Review  |  Company News  |  Other News

Momenta, Teva, Mylan, Natco, Novartis autoimmune, generics news

Teva will lose exclusivity for Copaxone glatiramer acetate on May 24, 2014, more than a year sooner than the company had previously expected, after the U.S. Court of Appeals for the Federal Circuit invalidated a process patent held by Teva covering the multiple sclerosis (MS) drug. The patent, U.S. Patent No. 5,800,808, was set to expire on Sept....

Read the full 279 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >